Sirukumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Sirukumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IL6
Clinical data
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6450H9926N1690O1998S46
Molar mass 144.6 kg/mol
 ☒N☑Y (what is this?)  (verify)

Sirukumab (INN, USAN) (developmental code name CNTO-136) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).

Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor[2]

Clinical trials[edit]

Rheumatoid arthritis[edit]

It has started clinical trials.[3] and reported some phase II results.[2]

In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[4] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[5]

Other[edit]

The drug is currently in phase II clinical trials for the treatment of depression.[6]

See also[edit]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
  2. ^ a b Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
  3. ^ A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy, clinicaltrials.gov
  4. ^ Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis. Dec 2015
  5. ^ IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab. Jan 2017
  6. ^ adisinsight